04:32 PM EDT, 05/06/2024 (MT Newswires) -- Profound Medical ( PROF ) , a medical device company, after trade Monday said a total of 25 paper, poster and podium presentations highlighted the company's Transurethral Ultrasound Ablation (TULSA) procedure's "ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer and/or benign prostatic hyperplasia patients" have been made at major medical meetings already in 2024.

The TULSA system "combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue".

"The TACT 5-year clinical trial data, along with multiple real-world reports on the safety, efficacy and durability of TULSA from U.S. commercial centers, such as Mayo Clinic in Florida, Busch Center in Georgia, and UT Southwestern Medical Center in Texas, as well as international user sites, like Sapporo Hokuyu Hospital in Japan, ALTA Klinik in Germany, and Turku University Hospital in Finland, add to the growing body of evidence supporting the potential of TULSA as a mainstream treatment for prostate disease," Arun Menawat, Profound's chief executive, said in a release

Profound shares closed down C$0.02 to C$10.04 on the Toronto Stock Exchange.